Benjamin L. Palleiko is the CEO of KalVista Pharmaceuticals, a biotech company focusing on innovative treatments. He stepped into this role on March 6, 2023, after serving as the President and Chief Financial Officer. His journey in the biotech scene...

Benjamin L. Palleiko is the CEO of KalVista Pharmaceuticals, a biotech company focusing on innovative treatments. He stepped into this role on March 6, 2023, after serving as the President and Chief Financial Officer. His journey in the biotech scene includes significant positions at Regal Healthcare and Ore Pharmaceutical Holdings, plus he co-founded Cielo Therapeutics, a private oncology company. An interesting part of his background is that he served as a Naval Aviator before shifting gears into finance and biotech. Palleiko holds a degree in Quantitative Economics from Tufts University and earned his MBA from the University of Chicago. In 2023, he earned $720,102 in total compensation, comprising a salary of $514,500 and a cash bonus, highlighting his strong performance in executing the company’s objectives. His vision for KalVista includes ambitious plans to further breakthrough therapies, showing his commitment to making a difference in the pharmaceutical industry.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other KalVista Pharmaceuticals CEOs

K

Benjamin L. Palleiko

CEO of KalVista Pharmaceuticals

Sector of Economy

Healthcare

CEO of KalVista Pharmaceuticals for

2 years 3 months (Mar 2023 - Present)

Previous Experience

Unknown

Rivals

Competitors/colleagues of Benjamin L. Palleiko

Holdings

See how much did Benjamin L. Palleiko make over time.

Benjamin Palleiko has significant stakes with KalVista Pharmaceuticals, known by the ticker KALV. In 2023, his total compensation reached $720,102, reflecting his key role in the company. Initially appointed as Chief Financial Officer in 2016 during a reverse acquisition, his...

Benjamin Palleiko has significant stakes with KalVista Pharmaceuticals, known by the ticker KALV. In 2023, his total compensation reached $720,102, reflecting his key role in the company. Initially appointed as Chief Financial Officer in 2016 during a reverse acquisition, his influence has grown as he took on the CEO position. He has been strategically positioned throughout his tenure. His earnings package this year, while substantial, reflects the goals of the company that focus on creating value and innovative treatment options. His past as an investment banker at top firms adds depth to his understanding of market movements, important for guiding KalVista’s direction.

Total Stock Sold

$3.16M

KALV

$3.16M

206,261 KALV shares

What if they kept their stock?

If Benjamin L. Palleiko didn't sell their stock, today they would have:
Extra KALV206,261 shares worth $2.50M.
This is -20.94% and $661.03K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Benjamin L. Palleiko.

KALV

$74.36K

KALV at $9.75/share

Dec 6, 2024

Sale

KALV

$133.29K

KALV at $9.26/share

Nov 17, 2024

Sale

KALV

$89.62K

KALV at $12.19/share

Sep 6, 2024

Sale

KALV

$170.77K

KALV at $12.01/share

Aug 17, 2024

Sale

KALV

$86.07K

KALV at $11.53/share

Jun 6, 2024

Sale

KALV

$258.34K

KALV at $11.76/share

May 17, 2024

Sale

KALV

$321.85K

KALV at $14.11/share

Feb 17, 2024

Sale

KALV

$613.20K

KALV at $15.01/share

Feb 14, 2024

Sale

KALV

87,500 shares

KALV

Feb 11, 2024

Received

KALV

$107.05K

KALV at $8.23/share

Nov 17, 2023

Sale

Compensation History

See how much did Benjamin L. Palleiko make over time.

In 2023, Benjamin L. Palleiko's total compensation package was $720,102. This included a base salary of $514,500 and a cash bonus of $180,075 for meeting specific company performance goals. His bonus structure aims to incentivize achieving ambitious targets that align with KalVista's long-term business objectives. Unlike prior years, there was no vested stock or granted options reported, which may highlight the company's current focus on cash incentives over equity compensation. The overall compensation is reflective of Palleiko's importance in steering Kalvista through the biotech landscape towards innovative treatments, particularly in the realm of rare diseases. His financial acumen gathered from previous roles adds to his effectiveness in this position.

Year

2023

Total Compensation

$707.10K

Salary

$514.50K

Board Justification

We seek to ensure that the total compensation paid to our executive officers is reasonable and competitive, structured around the achievement of individual performance and near-term corporate targets as well as long-term business objectives.

Bonus

$180.08K

Board Justification

The amount reported in the Bonus column represents the annual cash discretionary bonuses earned by our NEOs pursuant to the achievement of certain Company and individual performance objectives.

Other

$12.53K

Board Justification

The amounts reported in the All Other Compensation column consist of Company contributions to the 401(k) Plan.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

The performance objectives for our executive officers do not have specific financial or corporate targets associated with them.

Other KalVista Pharmaceuticals CEOs

Here are other CEOs of KalVista Pharmaceuticals

T. Andrew Crockett

Ex-CEO of KalVista Pharmaceuticals

March 2021 - March 2024